CML-457: Artificial Intelligence in Chronic Myeloid Leukemia: Assessing the Accuracy and Clinical Utility of Large Language Model
“AI is everywhere. Is it useful in CML? This study tests three different AI engines in their ability to answer 25 clinically meaningful questions. Do they work? Is one better than the other? Come find out.”
CML-731: Efficacy of Olverembatinib in Patients With Chronic-Phase Chronic Myeloid Leukemia With Prior Resistance to Ponatinib or Asciminib and ASXL1 Mutations
“There are many TKIs. Are the new ones useful? This study looks at the use of olverembatinib in CML cases resistant to ponatinib and asciminib. The drug has notable activity in this setting, including patients who also harbor ASXL1 mutations.”
CML-929: Validation of a Prognostic Score in Blast-Phase CML: A Cure CML Consortium Analysis
Blast crisis remains a problem in CML. This study provides validation of a prognostic risk score for patients in blast crisis. The model appears useful in categorizing patients into different risk groups with clinically meaningful different survival times.
CML-1050: ASC4FIRST Week 144 Analysis: Continued Superior Efficacy and Favorable Safety of Asciminib vs Investigator-Selected Tyrosine Kinase Inhibitors in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
“This is a week 144 analysis of newly diagnosed CML cases treated on the ASC4FIRST study. Do the earlier very encouraging early results hold up with longer follow up? Spoiler alert: Yes.”
Leave feedback about this